Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sincere CoTSE:7782 +0.20%84 Debt-to-Equity is 0.61 as of Jun. 2026, which is 118% above its 10-year median of 0.28. GuruFocus rates TSE:7782 with a GF Score™ of 84/100 and a GF Value™ of 円636.53 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 697 Medical Devices & Instruments companies, Sincere Co ranks worse than 74.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sincere Co's Debt-to-Equity or its related term are showing as below:
TSE:7782'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.28 Max: 0.95
Current: 0.61
During the past 12 years, the highest Debt-to-Equity Ratio of Sincere Co was 0.95. The lowest was 0.09. And the median was 0.28.
TSE:7782's Debt-to-Equity is ranked worse than 74.18% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs TSE:7782: 0.61
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sincere Co Debt-to-Equity Related Terms
Sincere Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sincere Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7782 vs ISRG, BDX, RMD: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Sincere Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sincere Co Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sincere Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sincere Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sincere Co (TSE:7782) has a Debt-to-Equity of 0.61 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sincere Co and its competitors. This is 118% above median its historical median of 0.28. Over the past decade, Sincere Co's Debt-to-Equity has ranged from 0.09 to 0.95. According to the industry distribution chart, Sincere Co ranks #517 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is Sincere Co's Debt-to-Equity too high?
Sincere Co's current Debt-to-Equity of 0.61 is 118% above median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.95. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Sincere Co's value of 0.61 is 154.2% above this industry median. Based on the distribution chart, Sincere Co ranks #517 out of 697 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sincere Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sincere Co's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sincere Co ranks #517 out of 697 companies for Debt-to-Equity. This places Sincere Co in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Sincere Co's value of 0.61 is 154.2% above this benchmark. Historically, Sincere Co's own Debt-to-Equity has ranged from 0.09 to 0.95 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 0.24, Sincere Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sincere Co's current Debt-to-Equity of 0.61 is 154.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sincere Co and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sincere Co's current Debt-to-Equity is 0.61, which is 118% above median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sincere Co stock overvalued right now?
Based on GuruFocus' analysis, Sincere Co (TSE:7782) is currently considered Modestly Undervalued. The stock's GF Value™ is 円636.53, compared to a current price of 円492.00 — trading 22.7% below its estimated fair value. The current Debt-to-Equity is 0.61, which is 118% above median its 10-year median of 0.28 and 154.2% above the Medical Devices & Instruments industry median of 0.24. Sincere Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sincere Co (TSE:7782), the current Debt-to-Equity is 0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sincere Co (TSE:7782) Overvalued in 2026?
Based on GuruFocus' analysis, Sincere Co stock appears to be undervalued.
The current stock price of 円492.00 is trading 22.7% below its estimated GF Value™ of 円636.53.
GuruFocus considers Sincere Co to be Modestly Undervalued.
Key valuation signals for TSE:7782:
Debt-to-Equity: 0.61 (118% above median its 10-year median of 0.28)
GF Value™: 円636.53 vs. price of 円492.00 (22.7% below fair value)
Industry Position: 154.2% above the Medical Devices & Instruments median (#517 of 697)
No single metric tells the full story. See the TSE:7782 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sincere Co Ltd is a Japanese firm engaged in the manufacturing and sale of contact lens.As a company that manufactures and sells contact lenses, which are high-regulated medical devices, it place the highest priority on product safety and quality control, while working closely with company's customers to develop a variety-of-products and sell them at affordable prices to please as many customers as possible. The company opperates domestically as well as internationally.
84GF Score
Get the complete analysis for TSE:7782
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7782 has been successfully added to your 
